Antibodies is a leading open-access journal published by MDPI since 2012, focusing on the dynamic and rapidly evolving field of immunology and drug discovery. With an E-ISSN of 2073-4468, this esteemed journal aims to provide a platform for the dissemination of high-quality research on all aspects of antibody research, including novel therapeutic strategies, diagnostic applications, and the molecular mechanisms of immune responses. With an impressive portfolio reflecting its standing, Antibodies boasts a 2023 category quartile ranking of Q1 in Drug Discovery and Q2 in both Immunology and Immunology and Allergy. This positions the journal prominently within its field, further underscored by its Scopus rankings that illustrate its influence and relevance, including a rank of #46 out of 157 in Drug Discovery. As a fully open-access journal, Antibodies ensures that groundbreaking research is readily available to a diverse audience, enhancing the collaborative efforts in the scientific community. The journal's headquarters in beautiful Basel, Switzerland, is a testament to its commitment to maintaining high standards of academic excellence while fostering innovation and knowledge exchange among researchers, professionals, and students worldwide.

BIOTECHNOLOGY LETTERS is a prestigious peer-reviewed journal that has been at the forefront of biotechnology research since its inception in 1979. Published by Springer, this esteemed journal serves as a vital platform for disseminating cutting-edge research in the fields of applied microbiology, bioengineering, and biotechnology, with a focus on innovative methodologies and technologies. With an impact factor reflecting its critical contribution to the discipline, BIOTECHNOLOGY LETTERS resides in the Q2 and Q3 tiers of various scientific categories, placing it among the notable journals in the biotechnological landscape. Although it offers traditional access options and does not feature open access, the journal embraces a global readership, encouraging submissions from researchers, professionals, and students eager to explore the dynamic advancements in biotechnology. Situated in the Netherlands, it continues to shape the future of the field through relevant, impactful research that addresses contemporary challenges and opportunities in medicine and beyond.

Tuberculosis is an esteemed peer-reviewed journal specializing in the fields of Infectious Diseases, Immunology, and Microbiology, published by Churchill Livingstone since 1974. With a scope aimed at advancing the understanding and management of tuberculosis and related infectious diseases, the journal provides a platform for innovative research findings, clinical practices, and policy discussions. It is ranked in the Q2 category for both Infectious Diseases and Microbiology (medical), reflecting its significance in the academic community and the impact of its published work. The journal's commitment to openness is evident in its access options, fostering wider dissemination of knowledge. With an impact factor that underscores its relevance, Tuberculosis serves as a crucial resource for researchers, healthcare professionals, and students dedicated to combatting these pressing health challenges. The journal operates from its production headquarters in Edinburgh, Scotland, ensuring a strong connection to the international research community.

Vaccine: X, published by Elsevier, is a premier open access journal dedicated to advancing research in the interdisciplinary fields of immunology and microbiology, infectious diseases, molecular medicine, and public health. With an ISSN of 2590-1362 and operating since 2019, the journal has rapidly established an influential role, achieving Q2 rankings in major categories such as Immunology and Microbiology, Infectious Diseases, and Public Health for 2023. Its commitment to disseminating cutting-edge research is evident from its broad scope, focusing on innovative vaccines and therapies that are critical for global health. Researchers and professionals will find value in the accessible nature of the journal, which has been recognized for its contributions to veterinary medicine as well, with a Q1 ranking in the miscellaneous veterinary category. The journal proudly showcases high-quality, peer-reviewed articles and welcomes submissions that push the boundaries of current knowledge, making it an essential resource for anyone involved in vaccine research and development.

The JOURNAL OF INFECTIOUS DISEASES, published by OXFORD UNIV PRESS INC, is a leading peer-reviewed journal dedicated to advancing the understanding of infectious diseases through high-quality research. With an impressive impact factor reflecting its prominence in the field—ranking in the Q1 category for both Immunology and Allergy and Infectious Diseases—this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike. Its extensive history, spanning over a century since its inception in 1904, highlights its established authority and commitment to the field. Based in the United Kingdom, the journal covers essential topics from clinical management to epidemiological trends, providing vital insights that inform practice and policy. Although the journal is not open access, it remains accessible to a wide audience, ensuring that critical research continues to drive innovation and best practices in infectious disease management.

BIOTECHNOLOGY AND BIOENGINEERING, published by Wiley, is a leading journal in the domains of applied microbiology, biotechnology, and bioengineering. With an ISSN of 0006-3592 and E-ISSN of 1097-0290, this journal has established itself as an essential resource for researchers, professionals, and students aiming to advance their knowledge and stay updated on cutting-edge innovations and methodologies in biotechnology. The journal has a commendable impact factor, and it is ranked in the second quartile (Q2) across multiple categories for 2023. This positions it favorably among its peers, underscoring its significance in the scientific community; for example, it ranks 23rd out of 127 in the field of Applied Microbiology and Biotechnology. As a hub of critical research findings and technological advancements, BIOTECHNOLOGY AND BIOENGINEERING invites contributions that push the boundaries of biotechnological applications, fostering a deeper understanding and development of sustainable solutions to current global challenges.

Minerva Biotechnology and Biomolecular Research is an emerging journal published by EDIZIONI MINERVA MEDICA, dedicated to the fields of biotechnology, biomolecular research, and applied microbiology. With an ISSN of 2724-542X and an E-ISSN of 2724-5934, this journal aims to foster deeper understanding and innovative advancements in these rapidly evolving disciplines. The journal has been categorized in the Q4 quartile across four categories in the 2023 rankings, highlighting its nascent yet growing influence within the scientific community. Operating on an open-access model, it enhances accessibility and encourages the dissemination of knowledge to researchers, professionals, and students alike. Set in the heart of Italy, specifically at CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY, Minerva Biotechnology and Biomolecular Research will continue to enrich the scientific literature from its inception in 2021 through 2024 and beyond, contributing to the global dialogue on biotechnological innovations and molecular research.

ANTIVIRAL RESEARCH, published by Elsevier, stands at the forefront of the study of antiviral agents and therapy, with a dedicated focus on advancing the understanding of viral infections and their mechanisms. The journal is recognized within the top tier of academic publications, belonging to the prestigious Q1 category in both Pharmacology and Virology as of 2023, ranking 12th out of 313 in Pharmacology and 11th out of 80 in Virology according to Scopus metrics, reflecting its significant impact in the field. With a long-standing history since its inception in 1959, it continues to serve as an essential platform for researchers and health professionals alike, sharing critical findings that drive innovation in antiviral therapeutics. Although it does not currently offer open access options, the journal’s rigorous peer-review process ensures that every published article meets high academic standards, providing invaluable insights for those dedicated to enhancing public health through virology research.

DRUG DEVELOPMENT RESEARCH is a premier interdisciplinary journal published by Wiley, focusing on the latest advancements in drug discovery, pharmacology, and toxicology. With an ISSN of 0272-4391 and an E-ISSN of 1098-2299, this esteemed publication has been a cornerstone in the field since its inception in 1981 and continues to provide cutting-edge research until 2024. Its rigorous peer-review process and strategic placement in Q2 of the Drug Discovery category, as well as ranking #60 out of 157 in Scopus, underscore the journal's relevance and influence, boasting a respectable 62nd percentile ranking. While the journal does not currently offer open access, it remains a vital resource for researchers, professionals, and students seeking to expand their knowledge on the processes of drug development, identifying new therapeutic targets, and assessing the efficacy and safety of novel compounds. Situated in Hoboken, NJ, this journal stands at the forefront of pharmaceutical innovation, making significant contributions to the advancement of medical science.

Infectious Diseases and Therapy is a premier scholarly journal published by Springer London Ltd, dedicated to advancing the understanding of infectious diseases through rigorous research and evidence-based therapy. With an esteemed Q1 ranking in both the Infectious Diseases and Microbiology (medical) categories, this journal is a vital resource for researchers, healthcare professionals, and students aiming to stay at the forefront of developments within the field. Launched in 2012, it has embraced an Open Access model, ensuring that groundbreaking studies and critical reviews are accessible to a global audience. Operating from its office in London, the journal encourages the dissemination of innovative therapies and diagnostic methods, fostering collaboration and knowledge sharing among the scientific community. In a landscape where infectious diseases pose significant health challenges, Infectious Diseases and Therapy stands as an essential platform for impactful research that can lead to improved healthcare outcomes worldwide.